Menthol-induced activation of TRPM8 receptors increases cutaneous blood flow across the dermatome

Dillon, Gabrielle A.; Lichter, Zachary S.; Alexander, Lacy M.

doi:10.1016/j.mvr.2021.104271

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, TRPM8 expression is upregulated in the skin and trigeminal ganglia of a mouse model of pruritus‐accompanying LL37‐induced rosacea and in the epidermis of skin biopsy samples from pruritus rosacea patients; these findings suggest TRPM8 is involved in rosacea pruritus 21 . Interestingly, topical application of menthol to healthy volunteers activated TRPM8 and increased cutaneous blood flow not only at the site of application but also across the dermatome 22 . In this context, topical activation of peripheral TRPM8 showed neuroprotective effects and mitigated ischemic stroke in mice 23 .…”

Section: Discussionmentioning

confidence: 92%

“…21 Interestingly, topical application of menthol to healthy volunteers activated TRPM8 and increased cutaneous blood flow not only at the site of application but also across the dermatome. 22 In this context, topical activation of peripheral TRPM8 showed neuroprotective effects and mitigated ischemic stroke in mice. 23 Furthermore, TRPM8 is involved in energy homeostasis, and TRPM8 agonists could be potential novel agents for treating obesity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A randomized, double‐blinded, vehicle‐controlled clinical trial of topical cryosim‐1, a synthetic TRPM8 agonist, in prurigo nodularis

Choi,

Lee,

Jung

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundPrurigo nodularis (PN) is an intensively pruritic skin disease that negatively influences quality of life. Cryosim‐1 (Intrinsic IB Spot) is a synthetic, selective transient receptor potential melastatin 8 agonist.AimsTo investigate the efficacy and safety of cryosim‐1 in PN patients.Patients/MethodsA randomized, double‐blinded, placebo‐controlled clinical trial including 30 patients was conducted. The numerical rating scale (NRS) of pruritus was evaluated before and 2 h after cryosim‐1 application at every visit.ResultsAt week 8, the mean pruritus NRS before serum application (4.7 ± 0.4 treatment, 6.1 ± 0.5 placebo; p = 0.045) and 2 h after serum application (2.8 ± 0.4 treatment, 4.3 ± 0.5 placebo; p = 0.031) were significantly lower in the treatment group, and the mean NRS for sleep disorder was significantly lower in the treatment group (2.2 ± 0.5 treatment, 4.2 ± 0.8 placebo; p = 0.031). The mean satisfaction scales for pruritus improvement were significantly higher in the treatment group (7.2 ± 0.6) than in the placebo group (4.0 ± 0.9; p = 0.005). There was no difference in TEWL between the two groups, and no adverse reactions were reported.ConclusionsCryosim‐1 is a safe and effective topical treatment for PN patients.

show abstract

Section: Discussionmentioning

confidence: 92%